Feng‐Hua Wang

6.7k total citations
126 papers, 2.9k citations indexed

About

Feng‐Hua Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Feng‐Hua Wang has authored 126 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Oncology, 54 papers in Pulmonary and Respiratory Medicine and 27 papers in Surgery. Recurrent topics in Feng‐Hua Wang's work include Gastric Cancer Management and Outcomes (39 papers), Colorectal Cancer Treatments and Studies (37 papers) and Cancer Immunotherapy and Biomarkers (21 papers). Feng‐Hua Wang is often cited by papers focused on Gastric Cancer Management and Outcomes (39 papers), Colorectal Cancer Treatments and Studies (37 papers) and Cancer Immunotherapy and Biomarkers (21 papers). Feng‐Hua Wang collaborates with scholars based in China, United States and Hong Kong. Feng‐Hua Wang's co-authors include Rui‐Hua Xu, Yuhong Li, Miao‐Zhen Qiu, De‐Shen Wang, Hui Luo, Feng Wang, Chao Ren, Dongsheng Zhang, Xiaoli Wei and Ying Jin and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Feng‐Hua Wang

122 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Feng‐Hua Wang China 31 1.5k 872 861 822 637 126 2.9k
Feng-Hua Wang China 27 1.4k 0.9× 625 0.7× 613 0.7× 825 1.0× 696 1.1× 56 2.5k
Jifang Gong China 29 1.7k 1.1× 785 0.9× 928 1.1× 603 0.7× 540 0.8× 147 2.9k
Kosei Maemura Japan 36 1.6k 1.1× 1.1k 1.3× 832 1.0× 977 1.2× 933 1.5× 158 3.4k
Roberto Petrioli Italy 28 1.6k 1.1× 508 0.6× 1.2k 1.4× 407 0.5× 855 1.3× 135 3.1k
Gerasimos Aravantinos Greece 36 2.3k 1.5× 975 1.1× 1.2k 1.4× 767 0.9× 1.3k 2.0× 205 4.5k
Mara Ghilardi Italy 29 1.8k 1.2× 402 0.5× 1.0k 1.2× 529 0.6× 627 1.0× 70 2.6k
Aurélie Cazes France 32 1.5k 1.0× 957 1.1× 1.6k 1.9× 727 0.9× 564 0.9× 108 3.8k
Angela Dalia Ricci Italy 31 1.7k 1.1× 679 0.8× 1.1k 1.2× 538 0.7× 1.1k 1.8× 97 3.0k
Pierre Fouret France 23 1.2k 0.8× 1.1k 1.3× 1.2k 1.4× 552 0.7× 624 1.0× 47 3.0k
Ming Zhang China 29 1.2k 0.8× 751 0.9× 588 0.7× 466 0.6× 637 1.0× 167 2.7k

Countries citing papers authored by Feng‐Hua Wang

Since Specialization
Citations

This map shows the geographic impact of Feng‐Hua Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feng‐Hua Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feng‐Hua Wang more than expected).

Fields of papers citing papers by Feng‐Hua Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feng‐Hua Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feng‐Hua Wang. The network helps show where Feng‐Hua Wang may publish in the future.

Co-authorship network of co-authors of Feng‐Hua Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Feng‐Hua Wang. A scholar is included among the top collaborators of Feng‐Hua Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feng‐Hua Wang. Feng‐Hua Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Qiu, Miao‐Zhen, Qingjian Chen, Qi Zhao, et al.. (2023). Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins. Cell Reports. 42(6). 112576–112576. 3 indexed citations
2.
Huang, Jinsheng, et al.. (2023). Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer. Therapeutic Advances in Medical Oncology. 15. 2630765–2630765. 3 indexed citations
3.
Chen, Yan‐Xing, Zixian Wang, Ying Jin, et al.. (2023). An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma. Cancer Cell. 41(5). 919–932.e5. 22 indexed citations
4.
Hu, Xingbin, Shulong Li, Zhiqi Yao, et al.. (2023). Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancer. Cancer Communications. 43(8). 909–937. 61 indexed citations
5.
Zeng, Liang, Shuhua Li, Shuoyu Xu, et al.. (2023). Cross-cohort analysis identified an immune checkpoint-based signature to predict the clinical outcomes of neuroblastoma. Journal for ImmunoTherapy of Cancer. 11(5). e005980–e005980. 6 indexed citations
6.
Wei, Xiaoli, Furong Liu, Jihong Liu, et al.. (2022). First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors. Nature Communications. 13(1). 7012–7012. 13 indexed citations
7.
Wei, Xiaoli, Feng‐Hua Wang, Xiaochen Zhang, et al.. (2022). Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor.. Journal of Clinical Oncology. 40(16_suppl). 3106–3106. 3 indexed citations
8.
Guan, Wen‐Long, Shi‐Xun Lu, Xiaoli Wei, et al.. (2022). Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literature. Clinical Medicine Insights Oncology. 16. 1363211146–1363211146. 12 indexed citations
9.
Liang, Jie‐Ying, Haocheng Lin, Jingwen Liu, et al.. (2021). A novel prognostic nomogram for colorectal cancer liver metastasis patients with recurrence after hepatectomy. Cancer Medicine. 10(5). 1535–1544. 10 indexed citations
10.
Wei, Xiaoli, Chao Ren, Feng‐Hua Wang, et al.. (2020). A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors. Cancer Communications. 40(8). 345–354. 33 indexed citations
11.
Yang, Lu-Ping, Zixian Wang, Ming-Ming He, et al.. (2019). <p>A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients</p>. Cancer Management and Research. Volume 11. 3993–4003. 7 indexed citations
12.
Wang, De‐Shen, Zexian Liu, Yun-Xin Lu, et al.. (2018). Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 68(7). 1152–1161. 138 indexed citations
13.
14.
Bai, Long, Feng Wang, Chao Ren, et al.. (2016). Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer. Medicine. 95(51). e4531–e4531. 13 indexed citations
15.
Zhang, Le, Jing Zeng, Feng‐Hua Wang, et al.. (2016). MGMT in colorectal cancer: a promising component of personalized treatment. Tumor Biology. 37(8). 11443–11456. 10 indexed citations
16.
Qiu, Miao‐Zhen, Yixin Zhou, Xinke Zhang, et al.. (2014). Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer. 14(1). 823–823. 55 indexed citations
17.
18.
Zhang, Yang, Liping Zhao, Pei-Yu Huang, et al.. (2012). Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology. 70(4). 611–615. 8 indexed citations
19.
Shen, Danhua, et al.. (2007). [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].. PubMed. 36(7). 457–60.
20.
Zhang, Dongsheng, Wenqi Jiang, Xiaoshi Zhang, et al.. (2003). [Predictive significance of serum 90K/Mac-2BP on chemotherapy response in non-Hodgkin's lymphoma].. PubMed. 22(8). 870–3. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Feng-Hua Wang Breakdown of academic impact, for papers by Jifang Gong Breakdown of academic impact, for papers by Kosei Maemura Breakdown of academic impact, for papers by Roberto Petrioli Breakdown of academic impact, for papers by Gerasimos Aravantinos Breakdown of academic impact, for papers by Mara Ghilardi Breakdown of academic impact, for papers by Aurélie Cazes Breakdown of academic impact, for papers by Angela Dalia Ricci Breakdown of academic impact, for papers by Pierre Fouret Breakdown of academic impact, for papers by Ming Zhang
Rankless by CCL
2026